Vertex Pharmaceuticals nosedived on Tuesday to hit a new all-time low following the termination of a clinical trial for an ...

I think that's the case with Vertex. Here are seven reasons why Vertex is a no-brainer stock to buy on the dip.

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Key Takeaways U.S. equities declined at midday following a soft services industry report and President Donald Trump's ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

U.S. stock futures are pointing higher after indexes surged Monday to rebound from last week's selloff. Nasdaq futures are 0.4% higher after the tech-heavy index gained 2% in the prior session, while ...

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) were trading at $393.83, down $78.44, or 16%, on top-line results from the phase II dose-ranging study evaluating the safety and efficacy of its ...